Published in J Pharm Sci on April 29, 2017
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife (2012) 5.18
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology (2005) 5.11
Mammalian ABC transporters in health and disease. Annu Rev Biochem (2001) 4.90
Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol (2014) 4.82
Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol (2008) 4.25
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest (1998) 3.66
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene (2003) 3.12
Impact of OATP transporters on pharmacokinetics. Br J Pharmacol (2009) 2.97
Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem (1990) 2.86
The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem (1998) 2.72
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (2016) 2.63
Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology (2012) 2.62
Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology (2010) 2.48
Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology (2006) 2.43
A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A (2005) 2.34
Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica (2008) 2.18
LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology (2001) 2.02
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res (1999) 2.00
Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest (1994) 1.98
Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica (2006) 1.96
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res (2008) 1.95
Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology (2008) 1.95
Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology (2001) 1.92
From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci (2001) 1.89
Nrf2 the rescue: effects of the antioxidative/electrophilic response on the liver. Toxicol Appl Pharmacol (2010) 1.85
Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT. Nat Genet (2003) 1.85
Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother (2008) 1.84
The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology (1997) 1.83
Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology (2006) 1.80
High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. J Pathol (2003) 1.80
Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology (2005) 1.79
Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem (2008) 1.78
Drug excretion mediated by a new prototype of polyspecific transporter. Nature (1994) 1.77
Organic cation transporters. Rev Physiol Biochem Pharmacol (2003) 1.77
Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem (2004) 1.76
Membrane topology of a cysteine-less mutant of human P-glycoprotein. J Biol Chem (1995) 1.75
Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol (2011) 1.69
Byler disease. Fatal familial intrahepatic cholestasis in an Amish kindred. Am J Dis Child (1969) 1.67
Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med (2014) 1.66
cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem (1996) 1.66
Bile acids as endogenous etiologic agents in gastrointestinal cancer. World J Gastroenterol (2009) 1.63
Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol (2006) 1.63
Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem (1997) 1.62
The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology (2002) 1.58
Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J (2003) 1.57
Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology (2006) 1.54
Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res (1998) 1.52
Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol (2008) 1.50
Transcriptional dynamics of bile salt export pump during pregnancy: mechanisms and implications in intrahepatic cholestasis of pregnancy. Hepatology (2014) 1.48
Synergistic interaction between genetics and disease on pravastatin disposition. J Hepatol (2014) 1.45
Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos (2007) 1.43
Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol (2003) 1.41
Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun (2001) 1.39
Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett (2005) 1.38
Progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol (2012) 1.35
ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J Biol Chem (2000) 1.34
Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos (2011) 1.33
New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med (2009) 1.32
Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology (2012) 1.31
Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology (2002) 1.30
Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab Dispos (2007) 1.29
Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A (2004) 1.27
Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handb Exp Pharmacol (2011) 1.25
Hepatobiliary transporters and drug-induced cholestasis. Hepatology (2006) 1.24
Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab Dispos (2011) 1.24
Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer (2001) 1.23
Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology (2001) 1.22
Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res (2008) 1.20
Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease. Biochim Biophys Acta (2010) 1.20
Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci (2006) 1.20
Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest (2002) 1.19
In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. Handb Exp Pharmacol (2011) 1.19
Isolation of a family of organic anion transporters from human liver and kidney. Biochem Biophys Res Commun (2001) 1.17
Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res (2001) 1.17
Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur J Pharmacol (2009) 1.16
Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs (2013) 1.16
Role of glycosylation in trafficking of Mrp2 in sandwich-cultured rat hepatocytes. Mol Pharmacol (2005) 1.14
Potent cytotoxicity of the phosphatase inhibitor microcystin LR and microcystin analogues in OATP1B1- and OATP1B3-expressing HeLa cells. Mol Cancer Ther (2007) 1.14
Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab Dispos (2008) 1.14
Altered localization and activity of canalicular Mrp2 in estradiol-17beta-D-glucuronide-induced cholestasis. Hepatology (2002) 1.14
Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos (2005) 1.14
Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. Cancer Sci (2007) 1.11
Mammalian multidrug-resistance proteins (MRPs). Essays Biochem (2011) 1.11
Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int (2005) 1.10
Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione. Mol Pharmacol (2000) 1.09
Novel liver-specific organic anion transporter OAT7 that operates the exchange of sulfate conjugates for short chain fatty acid butyrate. Hepatology (2007) 1.09
The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. J Hepatol (2004) 1.09
ABCC6 is a basolateral plasma membrane protein. Circ Res (2013) 1.08
Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Lab Invest (2003) 1.07
Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos (2008) 1.06
ABCC2/Abcc2: a multispecific transporter with dominant excretory functions. Drug Metab Rev (2010) 1.06
Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther (2005) 1.06
Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int (2007) 1.05
Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther (2002) 1.05
DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med (2011) 1.05
Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol (1997) 1.04
Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J Hepatol (2003) 1.04